A 25% reduced gadobutrol dose demonstrated non-inferior efficacy versus 100%-standard dose of gadoterate for contrast-enhanced brain MRI, particularly in patients undergoing multiple contrast ...

January 24, 2011 — An advisory committee for the US Food and Drug Administration (FDA) has recommended gadobutrol (Gadovist, Bayer) be approved for magnetic resonance imaging (MRI) of the ...

The launch of Pixxoscan expands GE HealthCare’s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers - Clariscan (gadoteric ...

GE HealthCare has today announced the launch of Pixxoscan, its macrocyclic, non-ionic Magnetic Resonance Imaging gadolinium-based contrast agent. Pixxoscan has been reviewed using a regulatory ...